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Abstract
Constipation is a frequently reported bowel symptom in the elderly with considerable impact on quality of life and
health expenses. Disease-related morbidity and even mortality have been reported in the affected frail elderly. Although
constipation is not a physiologic consequence of normal aging, decreased mobility, medications, underlying diseases,
and rectal sensory-motor dysfunction may all contribute to its increased prevalence in older adults. In the elderly there is
usually more than one etiologic mechanism, requiring a multifactorial treatment approach. The majority of patients
would respond to diet and lifestyle modifications reinforced by bowel training measures. In those not responding to
conservative treatment, the approach needs to be tailored addressing all comorbid conditions. In the adult population,
the management of constipation continues to evolve as well as the understanding of its complex etiology. However,
the constipated elderly have been left behind while gastroenterology consultations for this common conditions are at
a rise for the worldwide age increment. Aim of this review is to provide an update on epidemiology, quality of life
burden, etiology, diagnosis, current approaches and limitations in the management of constipation in the older ones
to ease the gastroenterologists’ clinic workload.
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Background
Chronic constipation is the prototype of functional gastro-
intestinal disorders (FGID) and a condition frequently
encountered in clinical practice, both in specialty office
(e.g., gastroenterology, geriatrics) and in general medicine.
About 30 % of the general population experiences
problems with constipation during life time [1, 2], with
elderly people and women being mostly affected. How-
ever, only a minority of patients (approximately 25 %)
uses medical treatments, whereas a considerable propor-
tion relies on alternative solutions, following advices
given in pharmacies or herbalist’s shops [1].
As for other FGID, such as functional dyspepsia or
irritable bowel syndrome (IBS), chronic constipation has
considerable impact on health expenses and quality of
life [3, 4]. Moreover, constipation can be associated with
relevant comorbidities. In the elderly, constipation is
significantly associated with lower urinary tract symp-
toms commonly improved by the restoration of regular
bowel movements [5]. In addition, constipation may lead
to faecal impaction and, although rarely, proceed to ster-
coraceous perforation of the colon, a life threatening
disease [6, 7]. Significant comorbidities are of particular
relevance in hospitalized or bedridden elderly patients,
who often have associated neurodegenerative diseases
such as Alzheimer’s or Parkinson’s disease [7].
One of the conceptual aspects that makes constipation
a clinical entity arduous to be managed is the absence of
a generally accepted definition of the disease. The trad-
itional criterion refers to a limited number of weekly
evacuations, although patients mostly complain of symp-
toms associated with difficult stool passage, such as
evacuation of hard or lumpy stools or the need of exces-
sive efforts and/or manipulation during defecation [2].
Epidemiological studies confirm that about 2–3 % of the
general population report a lower than normal number of
evacuations (<3 times) per week [8]. However, this criter-
ion tends to underestimate the considerably large amount
of patients actually suffering from this condition [2].
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Aim of this review is to define epidemiological, clinical
and pathophysiological features of chronic constipation,
as well as to evaluate the impact of this condition on
quality of life with a particular focus on elderly subjects.
An update on the management of constipation in the
elderly is also provided.
Review
Epidemiology
Similarly to most FGID, chronic constipation is more
commonly diagnosed in female patients (M/F ratio: 1: 2–3)
(1, 2). Constipation is a prevalent disorders in Western
countries that may affect up to 30 % of the general popula-
tion subject to the caveats that definitions of constipation
vary across studies (2). The financial burden of chronic
constipation is considerable, due to direct costs of the
healthcare system such as consultations, investigations,
and drug therapy [9].
About 85 % of constipated patients that require
medical care are already using laxatives and, every year,
in the United States approximately 82 million dollars are
spent for over-the-counter laxatives [10, 11].
Variability across studies on the prevalence of consti-
pation is due to several factors, including the age of the
population under investigation, the definition of consti-
pation used and “those who propose it” (i.e., reported by
patient or by a health care professional), as well as the
context in which the studies are carried out (i.e., com-
munity people or hospitalized patient). The prevalence
of constipation increases with age: in over 65 year-old
population studies, 26 % of women compared to 16 % of
men considered themselves to be constipated, while in a
84 year-old subgroup of patients, the proportion of suf-
ferers increased to 34 % in women and 26 % in men,
thus showing that age apparently leads to a substantial
levelling between sexes [12, 13]. Moreover, when the
prevalence of self-reported constipation was investigated
in a door-to-door survey of 209 community-dwelling
elderly 30 % of men and 29 % of women described
themselves as constipated at least once a month [14].
The primary symptom used to define constipation was
having to strain in order to defecate. The number of
chronic illnesses and the number of medications were
significantly related to constipation [14]. In addition,
frailty in older persons is very common and is associated
with immobility, poor food intake, and dehydration [15]:
an old study reported that constipation is present in
45 % of frail elderly persons [16]. In a community-based
study from Olmsted County (Minnesota, USA), which
included 100 patients aged 65 years-old or older, the
overall prevalence of constipation reported by patients
was 40 %: 24.4 % affected by functional constipation and
20.5 % by outlet dysfunction [17]. In a recent study, data
from the Australian Longitudinal Study of Ageing were
used to compare differences in constipation and laxative
use in 239 community elderly between 1992–93 and
2003–04. Over the years, the prevalence of self-reported
constipation increased from 14 to 21 % as well as laxa-
tive use from 6 to 15 %. Persistent chronic constipation
was reported by 9 % of the cohort. Female prevalence
was evident at both time points. Unexpectedly, the
association between laxative use and self-reported con-
stipation was poor (less than a third of cases) suggest-
ing sub-optimal management of constipation in the
elderly [18].
When defining constipation on the basis of the number
of weekly bowel movements, its prevalence decreases to
values of 10 % or lower using a cut-off of more than 2
evacuations or less per week. Interestingly, among people
who report constipation, only up to 10 % have less than
two bowel movements per week while almost half of them
have a daily bowel movement [14, 19, 20].
Constipation is more frequent among elderly patients
forced to periods of long-term care in hospital or nurs-
ing homes [21, 22]. A Finnish study showed a prevalence
of constipation or evacuation disturbances in 57 % of
women and 64 % of men among the general population
whereas the prevalence increased to 79 and 81 %, re-
spectively, among guests of a nursing home [23]. More-
over, up to 74 % of patients staying in long-term care
facilities uses laxatives on a daily basis [23]. A recent
prospective study on elderly inpatients aimed to explore
predictors associated with constipation during acute
hospitalization comparing stroke patients (n = 55) with
orthopaedic patients (n = 55) [23]. The incidence of “de
novo” constipation was high for both stroke (33 %) and
orthopaedic patients (27 %; p = 0.66) with bedpan use and
longer length of stay both increasing new-onset constipa-
tion [24]. The high rate of constipation in the elderly
population not only results in worsening of quality of life
and incremental economic costs, but can also increase the
risk of several complications including overflow faecal
incontinence thus prolonging hospitalization [20–22].
Quality of life
It is generally assumed that constipation affects un-
favourably patients’ quality of life (QOL) [2, 3]. Rather
unexpectedly, few solid data have been reported particu-
larly in the elderly population. A recent study by Rao
and co-workers analysed the effects of constipation on
QOL and psychological status in 158 subjects with 76
having a functional defecation disorder and 38 slow
colon transit constipation, while 44 were controls [25].
Subjects had to answer an 8-domain-questionnaire on
health status, including general health, vitality, social
functioning, emotional role (limitation of daily activities
causing emotional problems) and mental health. A
higher score was associated with a normal healthy status.
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Compared with patients with slow transit constipation
and control subjects, patients with dyssynergic defecation
had greater psychological distress and impaired health-
related quality of life (HR-QOL) [25]. The latter group
also showed a higher prevalence of paranoid ideation,
hostility and obsessive-compulsive disorder compared to
controls. Moreover, anxiety disorders, depression as well
as somatization and psychosis had a significantly higher
prevalence in both groups of patients with constipation
symptoms compared to controls [25].
Similarly, in 126 community-dwelling older adults,
respondents with chronic constipation had lower Short-
Form 36 (SF-36) scores for physical functioning, mental
health, general health perception, and bodily pain when
compared to respondents without constipation [26].
Data were replicated using the Psychological General
Well-Being (PGWB) index in 84 elderly subjects with
constipation showing lower PGWB total scores and
lower domain scores for anxiety, depression, well-being,
self-control and general health subscales, indicating
worse HR-QOL [3]. In addition, improvements on HR-
QOL were noted with effective treatment of constipa-
tion. Increasing weekly bowel movements was associated
with patients’ report of fewer urinary symptoms, better
sexual function and improved mood [5]. More recently,
in a study by Talley and co-workers, a questionnaire was
proposed to 100 people over the age of 65 years in order
to evaluate the impact of chronic constipation on their
quality of life [27]. A markedly higher prevalence of phys-
ical pain and a decrease in perception of health in consti-
pated patients compared to healthy controls was shown.
The study also confirmed that constipation negatively
affected both social and working life of patients [27].
Constipation is often associated with other symptoms
that influence negatively the daily life. Indeed, an epi-
demiological survey of constipation performed in Canada
showed that 32 % of constipated patients also need to
make efforts during defecation, 20 % eliminate hard stools
and 13 % has the feeling of incomplete evacuation or diffi-
cult stool passage [28].
Pathogenesis of constipation
From a pathogenetic point of view, chronic constipation
may itself be the disease, such as in primary forms, or be
part of a complex clinical picture, as in secondary forms.
This distinction is crucial for a proper management of
constipation.
Primary forms are further distinguished according to
their pathophysiological characteristics:
1) Slow transit constipation is characterized by pro-
longed transit time of stool through the colon and an
often reduced rectal sensitivity. In physiological condi-
tions colon motor activity is irregular, since it increases
after meals and after wake up while it decreases during
sleep [29]. It is characterized mainly by not propagated
waves, that allow the mixing of intraluminal content in
order to promote water and electrolytes absorption,
and also by propulsive waves, including high (HAPCs)
and low amplitude propagated contractions (LAPCs)
[29–31]. HAPCs promote rapid movements of intra-
luminal content and their presence is often associated
with evacuation [29].
Patients suffering from chronic constipation showed a
significantly HAPCs reduction (<5 per day) compared to
healthy controls [29–31]. In addition, gastro-colic reflex,
which exerts an important control on colonic peristalsis,
is deficient in patients with chronic constipation [32].
Thus, altered colonic motility plays a major role in the
slowdown of gastrointestinal transit in patients with
slow-transit constipation.
Slow transit constipation may be associated with
several endocrine and metabolic disorders, such as
hypothyroidism, hypercalcemia, porphyria or diabetes
mellitus, or may occur without any other significant
systemic, gastrointestinal or neurological diseases [2].
Recent studies on slow transit constipation aimed to
define alterations involved in cellular mechanisms of
intestinal coordination and motor function, such as
smooth muscle innervation (intrinsic or extrinsic) and
interstitial cells of Cajal (ICC, the pace-maker of gastro-
entero-colonic motility) [33]. In particular, histological
studies of biopsy specimens obtained from patients who
underwent colectomy for severe constipation have shown
alterations in both enteric neurons (apoptotic type which
justify a greater tendency to neurodegeneration) and
enteric glial cells (cells that support enteric neurons), lead-
ing to neuronal survival impairment; indeed, glial cells
produce neurotrophic factors, the lack of which could act
as a trigger signal of neurodegeneration [33–35]. Enteric
neuronal function abnormalities are associated with a
reduced amplitude of nerve inhibitor impulses on colon
circular muscular layer and, hence, with a lack of coordin-
ation between colonic segments [32].
Furthermore, surgical specimens obtained from pa-
tients undergoing colectomy for severe constipation have
shown a marked depletion of ICC [36]; how and why
these pacemaker cells alterations can influence neuro-
mediated mechanisms remains unclear in the patho-
physiology of slow transit constipation.
Colonic structural abnormalities can include neuropa-
thies/myopathies/mesenchymopathies, if ICC are affected,
or can be often combined (neuro-ICC-myopathies); fur-
thermore, the resulting dysfunction may diffusely involve
alimentary canal [36]. In this case constipation is part of a
generalized gastrointestinal motility disorder such as that
of chronic intestinal pseudo-obstruction [33, 36].
Two relevant aspects of slow transit constipation
pathophysiology have been noticed specifically in elderly:
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an increased deposit of collagen in the ascending colon,
which may cause both motor and compliance alterations
[34], and the presence of a greater number of binding
sites for plasmatic endorphins [37]. Both these mecha-
nisms, although apparently not connected to each other,
may contribute to slowing down the faecal transit,
leading to constipation.
2) Outlet obstruction: (constipation by difficult or
unsatisfactory expulsion of faeces from rectum) may
result from a lack of coordination between abdominal
muscles contraction and pelvic floor muscle relaxation
on straining, and/or from an obstructed perineal tran-
sit due to anorectal structural abnormalities or uro-
gynecological diseases [2].
The anal sphincter pressure reduction, both at rest
and on squeezing, may be caused by loss of muscular
mass and contractility along with a damage of the
pudendal nerve [17]. In particular, in the elderly it is also
associated with a lower elasticity of the rectal wall, with
a fibro-adipose degeneration and with an increased
thickness of the internal anal sphincter [38, 39]. There-
fore, during events such as anal stenosis or fissures,
proctitis, rectocele, haemorrhoids and uro-gynecological
disorders pelvic floor dysfunction may develop causing
both faecal incontinence and constipation on the aged
anorectum [39].
3) Constipation in IBS: in this case the typical symp-
tom is abdominal pain that tends to resolve or markedly
fade with evacuation. Although IBS is more common in
younger individuals, elderly subjects are not spared by
this FGID and the diagnosis might be overlooked [40]. A
recent survey of 230 consecutive elderly attending an
elderly care clinic, showed that symptoms suggestive of
IBS were reported by 22 % of the sample often associ-
ated with disabling non-colonic symptomatology [40].
However, a physician diagnosis was only made in one
patient without taking the chance of reducing the overall
burden of suffering in those potentially affected [40].
Different types of primary constipation may be present
alone or coexist in the same patient [41].
On the other hand, secondary forms of constipation
can be caused by several systemic diseases as well as by
some drugs of common use, including opiates, anticho-
linergics, calcium channel blockers and NSAIDs [2]. The
most common causes of secondary constipation are
summarized in (Table 1).
Constipation may be induced by all conditions that
alter the integrity of both structural and functional
components of neuro-muscular bowel system such as
amyloidosis, Hirschsprung’s disease and diabetes melli-
tus neuropathy, neurodegenerative diseases (Alzheimer’s
disease, PD and tauopathies in general) and paraneoplastic
syndromes [2, 12]. Thus, since the prevalence all these
conditions increases with age, also does constipation
[12, 22]. Moreover, dyssynergic defecation with outlet
dysfunction is relevant aetiology for constipation in PD
and correlates with the severity of the neurology
disease [42].
In addition, chronic constipation may occur in
patients suffering from psychological/psychiatric disor-
ders, endocrine abnormalities (especially hypothyroidism),
and hydroelectrolytic abnormalities, such as hypokal-
emia and hypercalcemia, all common conditions in the
elderly [22].
Finally, elderly patients often live a sedentary lifestyle,
reduce water intake resulting in dehydration, and eat less
fibre in their diet affecting gastrointestinal transit and
promoting constipation [14, 22]. We have recently re-
ported on the incidence of new onset constipation in six
out of ten healthy young males with symptoms suggest-
ive for outlet dysfunction after 1 month of experimental
bed rest [43].
Diagnosis
In clinical practice, dealing with a constipated patient
requires accurate collection of anamnestic data, with
particular attention to family history, medications (espe-
cially those that are known to slow down the gastro-
intestinal transit) and comorbidities, together with a
physical examination that includes digital rectal examin-
ation [2].
In an effort to improve diagnostic categorization, an
International group of experts has proposed a number
of symptom-based criteria for FGID, including chronic
constipation, known as the Rome criteria. In Table 2 are
Table 1 Common causes of secondary constipation
Drugs Anabolic steroids, analgesics, opioids (codeine),
NSAIDs, anticholinergics, anticonvulsivants,
antidepressants, antihistamines, antihypertensives
(verapamil e clonidine), anti-Parkinsonian,




Amyloidosis, Chagas disease, connective
tissue disorders, CNS lesions, autonomic
diabetic neuropathy, Hirschprung’s disease,
multiple sclerosis.
Idiopathic Paraneoplastic syndromes, Parkinson’s disease,
dementia, scleroderma, post-viral colon-paresis,








diverticolitis, rectocele, hernia, foreign bodies,
faecal impaction, IBD and complications.
Anorectal abnormalities: anal stenosis or fissures,
proctitis, rectocele, haemorrhoids.
Hypothyroidism, diabetes mellitus, pregnancy and
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listed the main criteria as reported in the latest edition
(Rome III) [41]. These, together with the exclusion of
alarm symptoms (such as rapid weight loss, hematoche-
zia, family history of colorectal cancer or inflammatory
bowel disease, positive faecal occult blood test, iron defi-
ciency anaemia and a recent onset constipation) may
lead to the diagnosis of functional constipation, often
avoiding unnecessary and costly examinations. The pres-
ence of any alarm symptom requires further investiga-
tions, including colonoscopy.
While the diagnostic predictivity of Rome III criteria
in irritable bowel syndrome-related constipation has
been evaluated in several studies, data on chronic consti-
pation are still lacking [44]. In addition, although often
applied in clinical trials the Rome III criteria are not
commonly used in the clinical practice [44]. O the other
hand, the Bristol stool scale could be a useful tool in
daily practice [45]. This is a seven level scale based on
the texture degree and morphology of faeces, which
correlates with gastrointestinal transit times. The first
two levels are representative of slow intestinal transit,
while stool consistency levels of 6 and 7 correlate to an
accelerated transit and diarrhea [45].
A well performed digital rectal examination may reveal
the presence of morphology alterations of the pelvic
floor (proctitis, rectal prolapse, rectal cancer, etc.),
additionally allowing for functional evaluation of the
anorectum (anal sphincter tone, evacuatory dysfunction)
[2, 7].
Furthermore, rectal examination is highly relevant on
diagnosing faecal impaction, a major cause of bowel
obstruction in the elderly [7]. In some cases, faecal
impaction can induce pseudo-diarrhoea due to the
passage of fluid and mucus around the faecal conglomer-
ate (overflow) [7]. If clinically misinterpreted, pseudo-
diarrhoea can lead to the administration of anti-diarrheal
drugs that further aggravate intestinal obstruction [7].
Rectal examination can be integrated with the use of an
anoscope or a proctoscope, which allows a direct view of
anal canal and rectum [2]. A simple Foley catheter balloon
expulsion test has been proved reliable and useful test
to diagnose an evacuation disorder of both functional
and altered morphology origin [46]. In addition, to
obtain a complete evaluation a standard abdominal
radiograph and a barium enema could eventually be
considered to look for megabowel and/or massive stool
retention [47].
In the absence of alarm signs, a correct management
of constipated patients is based on the use of an empiric
therapy, followed by the observation of clinical effects,
which can lead the clinician to a specific diagnosis [47].
In non-responders to conservative treatment, some
functional tests are useful to clarify pathophysiological
changes in patients with constipation after consideration
of performing endoscopy.
A gastrointestinal transit time evaluation, which con-
sists in ingesting radio-opaque markers, followed by an
abdominal radiological evaluation to check the distribu-
tion of markers, allows us to differentiate slow transit
constipation (markers distributed along colic frame)
from outlet obstruction (markers located almost exclu-
sively in rectal ampulla) [31]. So far colonic manometry
had a minimal clinical value and has been used only
for research purposes [47]. The improvement of this
test with the spatio-temporal map evolution, through
high-resolution manometry, is expected to open new
clinical perspectives to the manometric assessment of
the colon [31].
Gastrointestinal and/or ano-rectal manometric tests
may be clinically useful to reveal an underlying neur-
opathy or myopathy of gut, as well as to determine if
motor patterns (inter-digestives and post-prandial) anom-
alies can be identified in the small intestine [33]. Some
years ago, a study by our group clearly showed that
approximately two thirds of patients with constipation
had small intestine motor abnormalities [48]. Thus, pro-
posing a colectomy to patients with severe slow transit
constipation, without having evaluated the motility of
both ano-rectum and small bowel by manometry,
should be avoided. Indeed, the more the motor disorder
is extended throughout the alimentary tract, the less is
the long-term therapeutic success of colectomy in con-
stipated patients [49]. In addition to standard tech-
niques, colonic transit can also be measured using the
wireless motility capsule (WMC) which simultaneously
provides valuable transit time information about the
stomach and small bowel as well. This becomes par-
ticularly relevant when a multi regional motility dis-
order is suspected and tolerance to invasive procedures
is limited. A recent WMC study on 161 FGID patients
has provided evidence of multiregional intestinal dis-
motility in approximately half of the subjects that was
poorly gained by the clinical picture [50].
Table 2 Rome III diagnostic criteria for chronic constipation
1-MUST INCLUDE TWO OR MORE OF THE FOLLOWING:
a. Straining during at least 25 % of defecations
b. Lumpy or hard stools in at least 25 % of defecations
c. Sensation of incomplete evacuation for at least 25 % of defecations
d. Sensation of anorectal obstruction/blockage for at least 25 % of
defecations
e. Manual maneuvers to facilitate at least 25 % of defecations
(e.g., digital evacuation, support of the pelvic floor)
f. Fewer than three defecations per week
2-LOOSE STOOLS ARE RARELY PRESENT WITHOUT THE USE OF LAXATIVES
3-INSUFFICIENT CRITERIA FOR IRRITABLE BOWEL SYNDROME
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In outlet obstruction, anorectal manometry detects
changes in the anal sphincters contraction and relax-
ation, related to the presence of faeces. These tests are
important not only for diagnostic purposes but also to
set therapies based on rehabilitation techniques such as
bio-feedback [51].
Finally, dynamic videoproctography or MR defecography
can be used to further investigate cases of constipation due
to obstructed defecation [47]. Diagnostic strategies do not
appear to depend upon age, but this needs to be evaluated
on a case-to-case basis.
Treatment
Non-pharmacological treatment, which consists in diet
and lifestyle modifications is traditionally considered the
first step of a comprehensive treatment program to
effectively manage constipation. [47]. A number of
patients would believe that they need to have a bowel
movement every day; counselling on simple lifestyle
changes may improve their perception of bowel regular-
ity and a diary log reporting on stool pattern and
consistency may be helpful as well [11]. In addition, pa-
tients should be educated on recognizing and respond-
ing to any urge to defecate. A regular daily routine,
starting with a light physical activity, is particularly
recommended. The optimal times to have a bowel
movement are soon after waking and after meals, when
normal colon accentuates its motor activity [29]. There-
fore, patients should be advised to attempt defecation
first thing in the morning and in the post-prandial inter-
vals to profit most of the gastro-colic reflex [29].
A gradually increasing intake of fluids and fibres up to
30 g/day is suggested [11, 12]. This goal can be achieved
by recommending patient to integrate the diet with
more fruits, vegetables and nuts in addition to adding
varying amounts of bran. However, in elderly patients,
increments in fluid intake should be monitored espe-
cially in those with cardiac and renal disease [12]. In a
classical study, this approach has been reported to fasten
colon transit time in the constipated elderly without
mirroring significant improvement on symptoms [52].
On the contrary, a recent small sized study reported on
the efficacy of diet and lifestyle modification on symp-
toms and QOL in 23 constipated elderly showing a
significant improvement on both parameters [53]. More-
over, the position paper of the American College of
Gastroenterology on constipation had concluded that
fibre are effective treatment in adults, but adverse
events, bloating, distension, flatulence, and cramping
may limit their use, especially if increases in fibre intake
are not introduced gradually [54]. In addition, fibres
appear to be scarcely useful not only in patients with
proven slow transit constipation, but also in those who
suffer from pelvic floor dysfunction [31]. Although very
rarely, bowel sub-obstruction secondary to high fibres
dietary intake have been reported in elderly patients
[55]. In an effort to overcome bran side effects a number
of soluble fibres have been developed among them: nat-
urally occurring (psyllium seeds), semi-synthetic (methyl
cellulose) and synthetic (calcium polycarbophil) [56].
These compounds might also be regarded as bulking
forming laxatives for the mechanism of increasing stool
bulk by holding liquid in the gut [56]. Psyllium and
calcium polycarbophil have both been shown more ef-
fective than placebo in randomized controlled trials [56].
However, low palatability and occurrence of side effects,
such as flatulence and abdominal bloating likely due to
fermentation by intestinal microbiota have been associ-
ated with high drop-out rates in the elderly [57]. Finally,
a recent randomized controlled trial (RCT) showed that
dried plums were more effective than psyllium on im-
proving bowel frequency and stool consistency in adults
with mild to moderate constipation [58].
Other currently available non-pharmacological treat-
ment options for constipation are probiotics. Nowadays,
probiotics are familiar to the public as the components
of bioyoghurts and dietary supplements, are widely avail-
able, and commonly prescribed. The faecal flora changes
markedly with age mostly by a fall in numbers of bifido-
bacteria [55]. However, it is still unclear whether this is a
cause or the effect of constipation. It has been repeatedly
reported that probiotics in the elderly may both shorten
bowel transit and soften stools most likely by the
increased short chain fatty acid concentration [59]. A
logical choice would be to consider probiotics as a main-
stay of treatment for their lack of side effects and
absence of inference with medications. Preliminary data
supported this consideration, but large, randomized,
controlled trials have failed to show a significant benefit
on the complex clinical picture of constipation in the
elderly [55, 59].
Biofeedback therapy to teach adequate defecatory
effort is effective treatment in adults with dyssynergic
defecation [51]. The treatment protocol employed in
most RCTs performed in the adult population includes
four steps: 1)Patient education on appropriate defecation
effort, 2) Straining training to improve abdominal pushing
effort, 3) Training to relax pelvic floor muscles while
straining by visual feedback of anal canal pressure or aver-
aged anal EMG activity, 4) Practice simulated defecation
by using inflated rectal balloon [60]. Some Centers include
optional sensory training which is intended to lower the
threshold for the sensation of urgency to defecate [60]. In
the older ones, data are limited to a single RCT reporting
on clinical and anorectal physiology benefit associated
with EMG-biofeedback treatment in 15 elderly patients
with dyssynergia when compared to an analogue control
group [61]. In community dwelling constipated elderly
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biofeedback might be considered a therapeutic option
for dyssynergic defecation, but larger RCT are eagerly
awaited [62].
Although widely practiced, stool softeners have limited
evidence in the management of constipation in the
elderly [62]. Suppositories and enemas may be used in
institutionalized patients to help rectal evacuation in an
effort to prevent faecal impaction [22]. Side effects such
as electrolyte imbalances and rectal mucosal damage
have been reported with the use of phosphate and
soapsuds enema, respectively. When indicated, tap water
enema is the safest way to go [22].
Pharmacological therapy
Usually, when simple changes to lifestyle and diet do
not improve constipation, the use of laxatives is recom-
mended [62]. However, the use of laxatives must be
individualized with special attention to cardiac and
renal co-morbid conditions, drug interactions, and side
effects particularly in the frail elderly [22, 62]. This
heterogeneous group of drugs includes many products
which differ in pharmacological characteristics and
mechanism of action, but all of them having the
common purpose of stimulating defecation or softening
the consistency of faeces in order to facilitate their
expulsion (Table 3). Many types of laxatives are now-
adays available, however we will focus mainly on those
with major indications for the treatment of chronic
constipation in the elderly.
Stimulant laxatives are a diverse class of agents
derived primarily from anthraquinones and diphenyl-
methanes [31]. These drugs have a stimulating and
irritating action on the intestinal mucosa that increases
its secretory activity, thereby increasing water content
in the intestinal lumen. In addition, these laxatives
have probably a direct action on the enteric innerv-
ation (the enteric nervous system), increasing intestinal
motor activity [55, 57]. To this class of laxatives belong
senna, cascara, rhubarb, aloe, bisacodyl and sodium
picosulfate [31]. Notwithstanding their limited cost,
stimulant laxative chronic use has historically been
discouraged based on anecdotal fears of potential
complications [62]. In classical studies, silver staining
studies suggested their chronic use may result in en-
teric neuropathies, including replacement of ganglia by
Schwann cells and losses of neurons in the smooth
muscle of the colon and myenteric plexus [31, 47].
More advanced techniques have failed to confirm these
findings [31, 47]. Melanosis coli (dark colour of colonic
mucosa) is a typical endoscopy finding in patients with
prolonged use of stimulant laxatives, but it does not
have a pathological significance [47].
In recent RCTs both bisacodyl and sodium picosulfate
proved effective on increasing the number of complete
spontaneous bowel movements/week compared to pla-
cebo in constipated adults, but data in the elderly are
lacking [62]. However, a senna fibre combination in 77
constipated elderly residents in long term hospital or
nursing home care improved stool frequency, stool
consistency, and ease of evacuation when compared to
lactulose [63].
Osmotic laxatives are hyperosmolar agents that cause
secretion of water into the intestinal lumen by osmotic ac-
tivity thus improving bowel transit and stool consistency.
Lactulose, lactitol and macrogol are the most commonly
and safest compounds used in the elderly [55, 57, 64].
Lactulose and lactitol are both synthetic, non-digestible
disaccharides that are fermented by colonic bacteria to
increase stool water content and soften the stool [57]. This
process may enhance proliferation of lactobacilli (prebiotic
Table 3 Laxative compounds commonly used to treat chronic constipation
Type Laxative agent Mechanism of action Possible side effects
Bulking forming laxatives Natural fibres (e.g., psyllium) Intraluminal H2o binding, bulk forming
and decrease stool consistency
Bloating, flatulence
Semi-synthetic fibres (es. methylcellulose)
synthetic fibres (e.g., Polyethylene glycol
polycarbophil: Macrogol)
Osmotic laxatives Magnesium hydroxide, magnesium
citrate, magnesium sulfate, sodium
phosphate.
Interstitial H2o binding hydroelectrolytic alterations
Disaccharides and
alditols
Lactulose, sorbitol. Interstitial H2o binding Bacterial fermentation with bloating
and flatulence (low efficacy in slow
transit constipation)
Emollients laxatives Paraffin oil, docusate sodium Intraluminal H2o binding, bulk forming
and decrease stool consistency
Discomfort, abdominal pain,
cramping
Stimulant laxatives diphenylmethane derivatives
(bisacodyl, sodium picosulfate)
Stimulating action on enteric nerves with
decrease in peristaltic contractions.
Discomfort, abdominal pain,
cramping
Anthraquinones (senna, aloe, cascara) Decrease in colic absorption of H2o
and electrolytes
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action) and shorten bowel transit by promoting stool
acidification [57].
In a multicenter trial of 164 patients including a group
of elderly, lactulose was found to be more effective on
improving bowel frequency by day seven compared with
laxatives containing senna, anthraquinone derivatives, or
bisacodyl [64]. In a similar study comparing osmotic
compounds sorbitol was as effective as lactulose on
improving constipation, but was cheaper and better
tolerated [65]. Lactitol efficacy has been extensively eval-
uated in the constipated adults, but the efficacy in the
elderly is limited [66]. A recent meta-analysis concluded
that the efficacy on improving symptoms of constipation
of lactitol and lactulose are similar as well as tolerance
to the drugs [66]. Finally, a double blind vs placebo
study conducted by Ouwehand et al. studied the effects
of a symbiotic combination of Lactitol and Lactobacillus
acidophilus NCFM on bowel function and immune
parameters in a small group of healthy elderly [67]. The
symbiotic preparation was more effective than placebo
on increasing bowel movements and improving gut
mucosal immune function, thus suggesting future thera-
peutic applications.
Among osmotic agents, polyethylene glycol (PEG) or
macrogol 3350–4000 is the one where sound evidence
of effectiveness on improving constipation in RCTs is
best provided [54]. PEG is made from organic, iso-
osmotic, non-absorbable polymers, that do not act by
modifying osmotic exchanges but by retaining water
introduced with diet within the intestinal lumen, hence
increasing the faecal mass and reducing stool consistency
[68]. Two pivotal RCTs, one in the US and the other in
Europe, have shown that PEG is more effective than
placebo on achieving long term treatment success in
constipated adults [69, 70]. In the US based one, treat-
ment success was defined as relief of modified Rome
criteria for constipation for 50 % or more of weeks of
treatment [69]. In this study the treatment effective-
ness was similar when a subgroup analysis involving
75 elderly patients was performed [69]. In a large sized
RCT, PEG 17 g daily was more effective than placebo
at 4 weeks on improving drug induced constipation, a
common problem in the elderly [71]. In a multicenter,
placebo controlled study, PEG was shown to correct
bowel movements also in IBS adult patients with con-
stipation, but with no significant effects on digestive
symptoms [72]. Bloating and flatulence represent the
most frequent side effects of osmotic laxatives with
some PEG studies failing to report on the total
number of side effects [54]. A recent meta-analysis,
showed that PEG, compared to placebo or to other
laxatives (usually lactulose), significantly increased the
number of bowel movements per week in constipated
adults [73].
However, two recent reviews concluded that despite
increasing efforts on including the elderly in RCTs, most
studies on the use of laxatives in constipated older adults
provide limited evidence for small sample size and meth-
odology biases [57, 62]. In addition, severe laxative side
effects as dehydration, electrolyte imbalances, allergic
reaction, and hepatotoxicity have all been reported in
the elderly suggesting a tailored approach in this poten-
tially frail population [22].
Despite the wide range of laxatives, it is estimated that
about half of constipated patients do not achieve satis-
factory results with the drugs so far described [74].
Thus, new products based on more physiological mecha-
nisms of action have been developed in the attempt to
treat a larger share of constipated subjects [54, 62].
Among the new therapeutic options for constipation,
emerging drugs in clinical practice include pro-secretory
products (lubiprostone and linaclotide) and serotonergic
agents (Table 4) [54, 74].
Among drugs with intestinal secretagogue action, lubi-
prostone acts by activating type 2 chloride channel
(CCl2), located in the apical membrane of enterocytes
[75]. This effect determines chloride secretion in the
intestinal lumen followed by passive diffusion of sodium
and water [75]. It therefore causes an increase in faecal
content of water, which increases the distension of intes-
tinal walls with activation of the peristalsis, without hav-
ing a direct effect on smooth muscle of digestive tract
[76]. Lubiprostone at a dosage of 24 μg twice daily has
been consistently shown in RCTs more effective than
placebo on increasing number of spontaneous bowel
movements (SBM) per week as well as improving stool
consistency, straining, and constipation severity in the
adult population [76–80]. The percentage of elderly
patients included in the RCTs varied, but in one of these
studies 10 % of the participants were elderly [78]. More-
over, data from three open-label clinical trials were com-
bined to obtain a pool of elderly patients with chronic
idiopathic constipation and published as abstracts sug-
gesting similar benefit [80]. However, extrapolation of
the results of clinical trials performed in the overall adult
population to elderly patients must be done with caution
and additional RCTs are warranted before confirming
the efficacy of the treatment in elderly patients. While it
does not cause electrolyte disturbances, lubiprostone
evokes nausea (30 % of patients), and headache, probably
due to its prostaglandin-like structure [77, 79]. Never-
theless, this drug appears to be tolerated more by older
people since side effects appear to be less frequent than
in younger people [80].
Linaclotide is a receptor agonist of guanylate cyclase C,
located on the apical side of intestinal epithelial cells [81].
This drug causes an increase in intra and extra-cellular
cyclic guanosine monophosphate, which is followed by an
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increase in secretion of chloride, bicarbonate and water
into intestinal lumen, resulting in an activation of the peri-
stalsis and acceleration of the intestinal transit [81]. The
administration of linaclotide (150–300 micrograms a day)
causes an increase in the number of complete SBM per
week and reduces stool consistency and straining during
defecation [81–84].
In a study by Rao and colleagues, among 1602 pa-
tients with severe abdominal symptoms (44 % of sub-
jects had bloating, 44 % fullness, 32 % discomfort, 23 %
pain and 22 % cramping, with considerable overlap
among symptoms), 805 were treated with linaclotide
while 797 received placebo [84]. In patients with severe
symptoms, linaclotide reduced all abdominal symp-
toms; mean changes from baseline severity scores
ranged from −2.7 to −3.4 for linaclotide vs −1.4 to −1.9
for placebo (P < .0001) [84]. Linaclotide improved glo-
bal measures (P < .0001) and IBS-QOL scores (P < .01)
compared to placebo [84]. In one of the pivotal study,
10 % of the whole sample where elderly subjects, who
showed similar results in safety and improvement of
weekly spontaneous bowel movements, stool consistency,
straining, abdominal discomfort, and quality of life to the
entire study population [83]. However, solid data on the
efficacy and safety of Linaclotide in the constipated elderly
are still lacking. The most common side effect is repre-
sented by a dose-dependent diarrhoea, but less than 5 %
of patients are reported to discontinue treatment due to
side effects [81–84].
After the withdrawal of cisapride from distribution in
2000 and the significant restrictions in the use of tega-
serod (not marketed in Europe), new serotonergic drugs,
including prucalopride, velusetrag and norcisapride, have
emerged as effective new treatment options for chronic
constipation [85]. To understand the mechanism of
action of these drugs is necessary to analyse the basis of
the physiological mechanisms of gastrointestinal motility
[85]. Mechanical and chemical stimulation on the intes-
tinal walls evokes peristalsis, a motor pattern fundamen-
tal for life of any living being with a gastrointestinal
tract [85]. In fact, bolus (or endoluminal enteric con-
tent) evokes distortion/stimulation of enterochromaffin
cells (cells containing a biogenic amine, serotonin or
5-hydroxytryptamine, 5-HT) that, distributed along
the surface of digestive tract mucosa, react by secret-
ing 5-HT. This mediator activates neural circuits that
trigger peristalsis by binding to specific receptors at
the level of enteric neurons (myenteric and submuco-
sal plexus) [74, 85].
Among the seven types of serotonin receptors, 5-HT4
possesses a strong excitatory activity on neurons of the
myenteric plexus causing release of acetylcholine and
producing an increase in peristaltic movements [74, 85].
In this perspective, prucalopride is a high affinity agonist
of 5-HT4 receptors, has high bioavailability and is not
metabolized by cytochrome P3A4 which is associated
with fewer interactions with other active ingredients,
compared to other 5-HT4 receptor agonists [85]. The
safety and efficacy of prucalopride in constipation has
been evaluated in three large sized trials [86–88]. All stud-
ies were 12 weeks in duration with similar design: multi-
center, randomized, double-blind, placebo-controlled, and
parallel group [86–88]. To be included patients had to
report infrequent defecation, hard stools and/or frequent
straining resistant to laxatives. In all studies, the primary
efficacy endpoint was the proportion of patients having
Table 4 New treatment options for laxative-resistant chronic constipation
Drug Mechanism of action Effect Possible side effects
Lubiprostone Type 2 chloride channel (CCl2)
activator.
Chloride secretion in the intestinal lumen followed
by passive diffusion of sodium and water.
Nausea, headache.
Increase in faecal content of water with distension
of intestinal walls and activation of peristalsis and
acceleration of intestinal transit.
Linaclotide Plecanatide Guanylate cyclase C receptor agonist. Increase of intra and extra-cellular cyclic guanosine
monophosphate.
Dose-dependent diarrhea.
Increase of secretion of chloride, bicarbonate and
water into intestinal lumen.
Activation of peristalsis and acceleration of intestinal
transit.
Prucalopride 5-HT4 serotonin receptor agonist. Excitatory activity of neurons of the myenteric plexus. Headache, nausea, diarrhea.
Norcisapride Release of acetylcholine.
Velusetrag Activation of peristalsis and acceleration of intestinal
transit.
Elobixibat Enantiomer of 1,5-benzothiazepine. Bond and inhibits the ileal bile acid transporter. Abdominal pain, diarrhea.
Increased stay of bile acid in the colon. Activation of
peristalsis and acceleration of intestinal transit.
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three or more complete SBM per week, averaged over the
12-week period, using an intention-to-treat analysis.
Secondary endpoints included average increase of one or
more complete SBM per week, patient subjective satisfac-
tion, QOL questionnaires, changes in bowel symptoms,
stool consistency and straining at stool. All RCTs were
concordant on reporting Prucalopride as effective treat-
ment for chronic constipation in the adult population non
responding to laxatives [86–88]. Most study participants
were females, the preferred schedule was 2 mg/daily, since
no differences in clinical efficacy were noticed between 2
and 4 mg schedules, the latter dose being associated with
more frequent side effects including headache, nausea
(usually mild and short-lived) and diarrhoea [86]. A
post-hoc analysis showed that prucalopride not only
favourably affects bowel movements, but also improves
anorectal and abdominal symptoms including pain,
bloating and distension [87]. The efficacy of prucalo-
pride has also been tested short term in the constipated
older ones [88]. Three hundred chronically constipated
patients aged 65 years and over were randomized to
receive prucalopride at the dosage of 1 mg, 2 mg, 4 mg
or placebo once daily for four weeks. Approximately
one third of study participants were males. Inclusion
criteria, primary and secondary outcome parameters
were the same as the pivotal studies run in the adult
population [86]. Additional testing on cardiovascular
function was performed. Prucalopride, in the dose
range tested (1–4 mg once daily) was effective treat-
ment for constipated elderly improving both symptoms
and quality of life [88]. The lowest schedule was as
effective as the 4 mg/day and the Authors speculated a
potential drug clearing slower than in the adult popula-
tion. The drug was safe and well tolerated with head-
ache as the most commonly reported side effects (6.6 %
on 1 mg schedule). In addition, the safety and effective-
ness of Prucalopride have also been confirmed by a
small sized RCT on 84 elderly nursing home residents
with chronic constipation resistant to laxatives [89]. In
both studies, prucalopride did not cause QT prolonga-
tion (reported in patients treated with cisapride) or
other vascular disorders (i.e., ischemic colitis as rarely
reported in tegaserod trials) [88, 89].
The new horizons in the treatment of chronic constipa-
tion include a variety of new compounds, such as other se-
rotonergic drugs (velusetrag and norcisapride, both 5-HT4
receptor agonists) as well as molecules inhibiting the bile
acid transporter (elobixibat) and a new guanylate cyclase-C
agonist (plecanatide) [85, 90–94]. Velusetrag in a recent
randomized-controlled trial study of 4 weeks was found to
be effective and well tolerated in patients with chronic con-
stipation [90], while in a pharmacodynamics study norcisa-
pride has been shown to accelerate colonic transit in
healthy volunteers [91]. Elobixibat, an enantiomer of 1,5-
benzothiazepine, acts locally in the lumen of the gastro-
intestinal tract, binding and inhibiting the ileal bile acid
transporter, thereby increasing bile acid content in the
colon [85]. A randomized phase II placebo-controlled
study with 3 different doses of elobixibat, demonstrated
that the number of complete SBM raised progressively
with the increase of the drug dosage compared to placebo
[92]. Abdominal pain and diarrhoea were reported as main
adverse events in this study [92]. Finally, similarly to lina-
clotide, plecanatide is a guanylate cyclase C agonist, which
leads to secretion of fluids into the intestinal lumen, facili-
tating bowel movements [85]. A phase I study assesses the
safety, tolerability, and pharmacokinetics of a single dose
(ranging from 0.1 to 48 mg) of oral plecanatide in 79
healthy controls. Plecanatide was demonstrated to be safe
and well tolerated, and no measurable systemic absorption
of oral plecanatide was observed at any of the oral doses
studied [93]. Moreover, a multicenter randomized trial
compared 12 weeks of treatment with plecanatide (0.3, 1
or 3 mg daily) with placebo in 946 patients with chronic
constipation. Plecanatide 3 mg was more effective than
placebo on improving number of CSBM/week, stool
consistency, straining and QOL score [94].
Conclusions
In conclusion, constipation is a common, self-reported
digestive symptom that affects up to 30 % of people in
Western countries and has considerable impact on
health expenses and quality of life. Older individuals are
particularly prone to it with a reported prevalence of up
to 50 % in community-dwelling elderly and up to 70 %
in nursing-home residents. Loss of mobility, medica-
tions, associated comorbidities, and rectal sensory-motor
dysfunction are as important as gut aging alterations in
causing constipation. Digital rectal exam and clinical his-
tory may help on identifying causes of constipation, but
more than one mechanism might be involved. Diet and
lifestyle modifications are often ineffective to manage
constipation in the elderly and a multifactorial approach
is suggested. Laxatives remain a mainstay to solve the
problem but safety concerns in the frail elderly should
be addressed. In laxative resistant constipation, several
new agents that target different underlying pathophysio-
logical mechanisms have been proved to be safe and
effective in adults, but only partially validated in the eld-
erly. Additional RCTs addressing management of consti-
pation in the elderly are needed to tailor treatment in
this complex population and to improve the quality of
life of these disabled patients.
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